Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.

Mol Neurodegener · 2016 · PMC4929720 · PMID 27363697

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Recent biochemical analyses of the brains from 3 patients treated with bapineuzumab showed a trend for reduction in Aβ42 accompanied by an increase in Aβ40 leading to an overall reduction in the Aβ42/40 ratio.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.